38 results
Page 2 of 2
8-K
EX-10.1
9jw 7efh8b75r7
13 Jun 16
ContraVir Completes Merger with Ciclofilin Pharmaceuticals
12:00am
8-K
EX-10.1
ksf9ev v1ym5
31 May 16
ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
12:00am
8-K
EX-10.1
zu7wlbywv0 bjq5
31 Mar 16
ContraVir Pharmaceuticals Appoints John Cavan as Chief Financial Officer
12:00am
S-8
EX-10.1
0yp10q z87aid84hsh8
4 May 15
Registration of securities for employees
12:00am
8-K
EX-10.1
vrdmy5g48ec1ubjw
15 Jan 15
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
12:00am
8-K
EX-10.1
es450
15 Oct 14
ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
12:00am
8-K
EX-10.1
b8evwhxwjvncmi4
26 Jun 14
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
qifluk luyzmqr4
20 Mar 14
ContraVir Appoints James Sapirstein as Chief Executive Officer and Board Member
12:00am
8-K
EX-10.1
vuldm1zif1ud i2
5 Feb 14
Entry into a Material Definitive Agreement
12:00am
10-12G/A
EX-10.7
f9t733ey 9rjn7ur
24 Dec 13
Registration of securities (amended)
12:00am
10-12G/A
EX-10.4
axnl fr15
21 Nov 13
Registration of securities (amended)
12:00am
10-12G/A
EX-10.5
epac7zeja04xmrl0dyf
21 Nov 13
Registration of securities (amended)
12:00am
10-Q
EX-10.1
lx221grq6hb6ez61 1q
19 Nov 13
Quarterly report
12:00am
10-12G/A
EX-10.4
s6nt70
20 Sep 13
Registration of securities (amended)
12:00am
10-12G
EX-10.2
0dsre
8 Aug 13
Registration of securities
12:00am
10-12G
EX-10.3
w01s84yf
8 Aug 13
Registration of securities
12:00am
10-12G
EX-10.1
qs4 juf3b
8 Aug 13
Registration of securities
12:00am